TY  - JOUR

T1  - Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

JO  - PharmacoEconomics

UR  - http://eprints.whiterose.ac.uk/141166/

PY  - 2018/12/13

AU  - Ren S

AU  - Squires H

AU  - Hock E

AU  - Kaltenthaler E

AU  - Rawdin A

AU  - Alifrangis C

ED  - 

DO  - DOI: 10.1007/s40273-018-0750-2

Y2  - 2024/10/22

ER  -